Attenuation of TNFSF10/TRAIL-induced apoptosis by an autophagic survival pathway involving TRAF2- And RIPK1/RIP1-mediated MAPK8/JNK activation

Autophagy

Volumn 8, Issue 12, 2012, Pages 1811-1821

  He, Weiyang ^a,b   Wang, Qiong ^b   Xu, Jennings ^b   Xu, Xiuling ^b   Padilla, Mabel T ^b   Ren, Guosheng ^a   Gou, Xin ^a   Lin, Yong ^b  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

Author keywords

Apoptosis; Autophagy; MAPK8 JNK; RIPK1 RIP1; TNFSF10 TRAIL; TRAF2

Indexed keywords

BECLIN 1; CARRIER PROTEIN; CELL PROTEIN; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN ATG7; PROTEIN BCL XL; PROTEIN RIPK1; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; AUTOPHAGY; BLADDER CANCER; CANCER CELL CULTURE; CELL PROTECTION; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN TISSUE; LUNG CANCER; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION;

EID: 84870909002     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.4161/auto.22145     Document Type: Article

References (40)

1. Abdulghani J, El-Deiry WS. TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets 2010; 14:1091-108; PMID:20819019; http://dx.doi.org/10. 1517/14728222.2010.519701
2. Stegehuis JH, de Wilt LH, de Vries EG, Groen HJ, de Jong S, Kruyt FA. TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives. Drug Resist Updat 2010; 13:2-15; PMID:20036602; http://dx.doi.org/10.1016/j.drup.2009.11.001
3. Leong S, Cohen RB, Gustafson DL, Langer CJ, Camidge DR, Padavic K, et al. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J Clin Oncol 2009; 27:4413-21; PMID:19652058; http://dx.doi.org/10.1200/JCO.2008.21.7422
4. Hellwig CT, Rehm M. TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies. Mol Cancer Ther 2012; 11:3-13; PMID:22234808; http://dx.doi.org/10.1158/1535-7163.MCT-11-0434
5. Lane D, Côté M, Grondin R, Couture MC, PichéA. Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3. Mol Cancer Ther 2006; 5:509-21; PMID:16546965; http://dx.doi.org/10.1158/1535-7163.MCT-05-0362
6. Song JJ, An JY, Kwon YT, Lee YJ. Evidence for two modes of development of acquired tumor necrosis factor-related apoptosis-inducing ligand resistance. Involvement of Bcl-xL. J Biol Chem 2007; 282:319-28; PMID:17110373; http://dx.doi.org/10.1074/jbc.M608065200
7. Wenger T, Mattern J, Penzel R, Gassler N, Haas TL, Sprick MR, et al. Specific resistance upon lentiviral TRAIL transfer by intracellular retention of TRAIL receptors. Cell Death Differ 2006; 13:1740-51; PMID:16470224; http://dx.doi.org/10.1038/sj.cdd.4401867
8. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001; 15:2922-33; PMID:11711427.
9. Lin Y, Devin A, Cook A, Keane MM, Kelliher M, Lipkowitz S, et al. The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase. Mol Cell Biol 2000; 20:6638-45; PMID:10958661; http://dx.doi.org/10.1128/MCB.20.18.6638-6645.2000
10. Wajant H. TRAIL and NFkappaB signaling - a complex relationship. Vitam Horm 2004; 67:101-32; PMID:15110174; http://dx.doi.org/10.1016/S0083-6729(04) 67007-5
11. Wajant H, Gerspach J, Pfizenmaier K. Tumor therapeutics by design: targeting and activation of death receptors. Cytokine Growth Factor Rev 2005; 16:55-76; PMID:15733832; http://dx.doi.org/10.1016/j.cytogfr.2004.12.001
12. Wang X, Chen W, Zeng W, Bai L, Tesfaigzi Y, Belinsky SA, et al. Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells. Mol Cancer Ther 2008; 7:1156-63; PMID:18483303; http://dx.doi.org/10.1158/1535-7163.MCT-07-2183
13. Chen W, Bai L, Wang X, Xu S, Belinsky SA, Lin Y. Acquired activation of the Akt/cyclooxygenase-2/Mcl-1 pathway renders lung cancer cells resistant to apoptosis. Mol Pharmacol 2010; 77:416-23; PMID:19933775; http://dx.doi.org/10. 1124/mol.109.061226
14. Li Z, Xu X, Bai L, Chen W, Lin Y. Epidermal growth factor receptor-mediated tissue transglutaminase overexpression couples acquired tumor necrosis factor-related apoptosis-inducing ligand resistance and migration through c-FLIP and MMP-9 proteins in lung cancer cells. J Biol Chem 2011; 286:21164-72; PMID:21525012; http://dx.doi.org/10.1074/jbc.M110.207571
15. Todde V, Veenhuis M, van der Klei IJ. Autophagy: principles and significance in health and disease. Biochim Biophys Acta 2009; 1792:3-13; PMID:19022377; http://dx.doi.org/10.1016/j.bbadis.2008.10.016
16. Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell 2011; 147:728-41; PMID:22078875; http://dx.doi.org/10.1016/j.cell.2011.10.026
17. Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 2005; 122:927-39; PMID:16179260; http://dx.doi.org/10.1016/j.cell.2005.07.002
18. Notte A, Leclere L, Michiels C. Autophagy as a mediator of chemotherapy-induced cell death in cancer. Biochem Pharmacol 2011; 82:427-34; PMID:21704023; http://dx.doi.org/10.1016/j.bcp.2011.06.015
19. Bonapace L, Bornhauser BC, Schmitz M, Cario G, Ziegler U, Niggli FK, et al. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J Clin Invest 2010; 120:1310-23; PMID:20200450; http://dx.doi.org/10.1172/JCI39987
20. Wu WK, Coffelt SB, Cho CH, Wang XJ, Lee CW, Chan FK, et al. The autophagic paradox in cancer therapy. Oncogene 2012; 31:939-53; PMID:21765470; http://dx.doi.org/10.1038/onc.2011.295
21. Mills KR, Reginato M, Debnath J, Queenan B, Brugge JS. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is required for induction of autophagy during lumen formation in vitro. Proc Natl Acad Sci U S A 2004; 101:3438-43; PMID:14993595; http://dx.doi.org/10.1073/pnas.0400443101
22. Han J, Hou W, Goldstein LA, Lu C, Stolz DB, Yin XM, et al. Involvement of protective autophagy in TRAIL resistance of apoptosis-defective tumor cells. J Biol Chem 2008; 283:19665-77; PMID:18375389; http://dx.doi.org/10.1074/jbc. M710169200
23. Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell 2010; 140:313-26; PMID:20144757; http://dx.doi.org/10.1016/j. cell.2010.01.028
24. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 2008; 4:151-75; PMID:18188003
25. Hou W, Han J, Lu C, Goldstein LA, Rabinowich H. Autophagic degradation of active caspase-8: a crosstalk mechanism between autophagy and apoptosis. Autophagy 2010; 6:891-900; PMID:20724831; http://dx.doi.org/10.4161/auto.6.7. 13038
26. Hou W, Han J, Lu C, Goldstein LA, Rabinowich H. Enhancement of tumor-TRAIL susceptibility by modulation of autophagy. Autophagy 2008; 4:940-3; PMID:18769107
27. Wei Y, Pattingre S, Sinha S, Bassik M, Levine B. JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. Mol Cell 2008; 30:678-88; PMID:18570871; http://dx.doi.org/10.1016/j.molcel.2008.06.001
28. Clem RJ, Cheng EH, Karp CL, Kirsch DG, Ueno K, Takahashi A, et al. Modulation of cell death by Bcl-XL through caspase interaction. Proc Natl Acad Sci U S A 1998; 95:554-9; PMID:9435230; http://dx.doi.org/10.1073/pnas.95.2.554
29. Zhou F, Yang Y, Xing D. Bcl-2 and Bcl-xL play important roles in the crosstalk between autophagy and apoptosis. FEBS J 2011; 278:403-13; PMID:21182587; http://dx.doi.org/10.1111/j.1742-4658.2010.07965.x
30. Allen JE, El-Deiry WS. Oxaliplatin uses JNK to restore TRAIL sensitivity in cancer cells through Bcl-xL inactivation. Gastroenterology 2011; 141:430-4; PMID:21699898; http://dx.doi.org/10.1053/j.gastro.2011.06.026
31. Korolchuk VI, Menzies FM, Rubinsztein DC. Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems. FEBS Lett 2010; 584:1393-8; PMID:20040365; http://dx.doi.org/10.1016/j.febslet.2009.12.047
32. Korolchuk VI, Mansilla A, Menzies FM, Rubinsztein DC. Autophagy inhibition compromises degradation of ubiquitin-proteasome pathway substrates. Mol Cell 2009; 33:517-27; PMID:19250912; http://dx.doi.org/10.1016/j.molcel. 2009.01.021
33. Lin A, Dibling B. The true face of JNK activation in apoptosis. Aging Cell 2002; 1:112-6; PMID:12882340; http://dx.doi.org/10.1046/j.1474-9728.2002. 00014.x
34. Ventura JJ, Cogswell P, Flavell RA, Baldwin AS Jr., Davis RJ. JNK potentiates TNF-stimulated necrosis by increasing the production of cytotoxic reactive oxygen species. Genes Dev 2004; 18:2905-15; PMID:15545623; http://dx.doi.org/10.1101/gad.1223004
35. Yu C, Minemoto Y, Zhang J, Liu J, Tang F, Bui TN, et al. JNK suppresses apoptosis via phosphorylation of the proapoptotic Bcl-2 family protein BAD. Mol Cell 2004; 13:329-40; PMID:14967141; http://dx.doi.org/10.1016/S1097-2765(04) 00028-0
36. Mahalingam D, Keane M, Pirianov G, Mehmet H, Samali A, Szegezdi E. Differential activation of JNK1 isoforms by TRAIL receptors modulate apoptosis of colon cancer cell lines. Br J Cancer 2009; 100:1415-24; PMID:19352384; http://dx.doi.org/10.1038/sj.bjc.6605021
37. Xu P, Das M, Reilly J, Davis RJ. JNK regulates FoxO-dependent autophagy in neurons. Genes Dev 2011; 25:310-22; PMID:21325132; http://dx.doi.org/10.1101/ gad.1984311
38. Wang X, Ju W, Renouard J, Aden J, Belinsky SA, Lin Y. 17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappaB pathway. Cancer Res 2006; 66:1089-95; PMID:16424045; http://dx.doi.org/10.1158/0008-5472.CAN-05-2698
39. Bai L, Chen W, Chen W, Wang X, Tang H, Lin Y. IKKbeta-mediated nuclear factor-kappaB activation attenuates smac mimetic-induced apoptosis in cancer cells. Mol Cancer Ther 2009; 8:1636-45; PMID:19509265; http://dx.doi.org/10. 1158/1535-7163.MCT-09-0068
40. Devin A, Cook A, Lin Y, Rodriguez Y, Kelliher M, Liu Z. The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation. Immunity 2000; 12:419-29; PMID:10795740; http://dx.doi.org/10.1016/S1074-7613(00)80194-6